[ASAP] Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with In Vitro and In Vivo Activity in Neurodegenerative Diseases

AI Summary

This article discusses the development of novel hybrid molecules containing Contilisant and Tubastatin A as potential HDAC inhibitors for the treatment of neurodegenerative diseases. The study shows that these polyfunctionalized indole derivatives have promising in vitro and in vivo activity, making them potential multitarget small molecules for therapeutic intervention.